Researchers examined data from more than 9,000 patients, sharing their findings at SCAI 2025.

The FDA has approved the balloon-expandable Sapien 3 TAVR platform from Edwards Lifesciences for treating asymptomatic severe aortic stenosis. This is the first time the agency has approved any TAVR technology to be used in asymptomatic patients. 

The approval of certain TAVR valves to be used in asymptomatic patients is expected to make a significant impact on patient care going forward. 

SCAI and SCCT have collaborated on a new document designed to get more interventional cardiologists to embrace CT-guided PCI going forward. 

The BATMAN technique is a safe, effective way to prevent LVOT obstruction during high-risk transcatheter mitral valve replacement, according to new data presented at SCAI 2025.

Cannabis use can be especially harmful for heart failure patients, according to new data presented at SCAI 2025.

Cardiologists are turning to leadless pacemakers more and more for cardiac pacing, but those devices have not previously been able to perform LBBAP. This new analysis includes new data on the world’s very first leadless LBBAP procedures. 

Srihari Naidu, MD, spoke to Cardiovascular Business about his plan to take SCAI in some bold new directions.

The study's lead author emphasized that stenting during CTO PCI procedures "should be considered safe and effective in the long term."

Philippe Genereux, MD, principal investigator of EARLY TAVR, presented new data at ACC.25 showing intervening early on crossover patients with asymptomatic severe aortic stenosis led to better outcomes and a reduced stroke rate.